Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 9/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATF1 | P18846 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15585227 | 0.80 | KDM4E (0.33) | ALDH1A1KDM4ESMN1; SMN2PIN1GAA | |
| SCHEMBL15585186 | 0.79 | KDM4E (0.33) | ALDH1A1KDM4ESMN1; SMN2PIN1 | |
| SCHEMBL1981633 | 0.78 | ALDH1A1 (0.46) | ALDH1A1KDM4ESMN1; SMN2PIN1GAA | |
| SCHEMBL15585226 | 0.77 | PIN1 (0.35) | ALDH1A1KDM4ESMN1; SMN2PIN1 | |
| SCHEMBL1471865 | 0.77 | QPCT (0.39) | ALDH1A1KDM4ESMN1; SMN2GAACYP1A2 | |
| SCHEMBL1996295 | 0.77 | ALDH1A1 (0.44) | ALDH1A1KDM4ESMN1; SMN2PIN1GAA | |
| SCHEMBL2437490 | 0.77 | ALDH1A1 (0.53) | ALDH1A1KDM4ESMN1; SMN2PIN1GAA | |
| SCHEMBL30786798 | 0.77 | ALDH1A1 (0.53) | ALDH1A1KDM4ESMN1; SMN2PIN1GAA | |
| SCHEMBL19103239 | 0.77 | P2RX3 (0.37) | HTTLRRK2KMT2A | |
| SCHEMBL29809151 | 0.77 | QPCT (0.39) | ALDH1A1KDM4ESMN1; SMN2GAACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3075730-B1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2018-10-24 | — | — | EP | disclosed |
| EP-2840080-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | FUJIFILM CORP (JP) | 2017-12-06 | — | — | EP | disclosed |
| EP-2840080-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | FUJIFILM CORP (JP) | 2017-12-06 | — | — | EP | disclosed |
| EP-2785699-B1 | 2-PHENYLAMINOPYRIMIDINE DERIVATIVES AS KINASE LRRK2 MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | GENENTECH INC (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-2785699-B1 | 2-PHENYLAMINOPYRIMIDINE DERIVATIVES AS KINASE LRRK2 MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | GENENTECH INC (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-2807152-B1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-2807152-B1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-2785709-B1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2017-05-10 | — | — | EP | disclosed |
| EP-2785709-B1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2017-05-10 | — | — | EP | disclosed |
| EP-3121173-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-01-25 | — | — | EP | disclosed |
| US-20090099219-A1 | ALKYNYLPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| EP-2022785-A1 | Alkynylpyrimidines as Tie2 kinase inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-02-11 | — | — | EP | disclosed |
| EP-2022785-A1 | Alkynylpyrimidines as Tie2 kinase inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-02-11 | — | — | EP | disclosed |
| WO-2008155140-A1 | ALKYNYLPYRIMIDINES AS TIE2 KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008155140-A1 | ALKYNYLPYRIMIDINES AS TIE2 KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
| EP-1963282-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES , THEIR PREPARATION AND USE AS DRUGS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-09-03 | — | — | EP | disclosed |
| US-20070232632-A1 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232632-A1 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232632-A1 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| WO-2007071455-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES , THEIR PREPARATION AND USE AS DRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099219-A1 | ALKYNYLPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | KDR, TIE1, FLT1 | ALDH1A1 952/4885KDM4E 995/4885SMN1; SMN2 790/4885 |
| US-20070232632-A1 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | TYMS, DPYD, DHFR | ALDH1A1 328/4885KDM4E 3039/4885SMN1; SMN2 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.